RESUMEN

Pain is one of the most common clinical symptoms of cancer patients, seriously affecting the quality of life of patients and bringing heavy mental and economic burden to families and society. The treatment of cancer pain in China is facing numerous challenges, one of which includes the irrational usage of analgesic drugs in clinical practice. As a strong opioid analgesic, transdermal fentanyl patch has been widely used due to its convenient clinical application and obvious therapeutic effect. Several basic-level hospitals and even general hospitals in China fail to appropriate the application of drugs in clinical application due to the lack of understanding of the pharmacological characteristics and clinical application of fentanyl transdermal patch by medical staff, seriously affecting the treatment quality. Therefore, it is imperative to strengthen the rational use and management of fentanyl transdermal patches. Accordingly, the initiation by the Cancer Rehabilitation and Palliative Treatment Professional Committee of the Hubei Anti-cancer Association launched the compilation of the "Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch" (from now on referred to as the "Guidelines") in Hubei Province, China. The experts in the preparation group are experts in many disciplines, such as medicine, pharmacy, and nursing. The expert group determines the outline, prepares the required regulations, and revises it repeatedly. Moreover, these experts put forward suggestions for revision to strictly control the accuracy and scientific authenticity of the contents of the "Guide". Finally, all experts of the preparation team certify and finalize the draft. This "Guide" prepared by experts of the Cancer Rehabilitation and Palliative Treatment Professional Committee of the Hubei Anti-cancer Association and the expert advisory group with joint efforts, aims to play a positive role in promoting the rational clinical use of fentanyl transdermal patch, reducing the mental and economic burden of patients, and ensuring medical quality and medical safety.

Asunto(s)

Fentanilo , Neoplasias , Humanos , Fentanilo/efectos adversos , Parche Transdérmico , Calidad de Vida , Analgésicos Opioides/efectos adversos , Dolor/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Administración Cutánea

RESUMEN

Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4, 2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.

Asunto(s)

Antineoplásicos , Carcinoma Hepatocelular , Neoplasias Hepáticas , Humanos , Antineoplásicos/uso terapéutico , Antineoplásicos/farmacología , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Neoplasias Hepáticas/patología , Compuestos de Fenilurea/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/uso terapéutico , China , Guías de Práctica Clínica como Asunto

RESUMEN

Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4,2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.

RESUMEN

Objective To investigate the usage of Shuxuening Injection in Chuzhou Hospital of Traditional Chinese and Western Medicine (hereinafter referred to as our hospital); To promote clinical rational usage of Shuxuening Injection. Methods A retrospective study was conducted to 297 cases of using Shuxuening Injection in our hospital from January 2016 to June 2016. Results In the 297 cases, 58.9% patients were over 60 years old, and indication coincidence rate of Shuxuening Injection was 52.2%. 91.2% single dose met the instructions and 6.7%solvent use met instructions. Shuxuening Injection in the joint medication also had irrational usage phenomenon. Conclusion There is irrational usage of Shuxuening Injection in our hospital, especially in indication and solvent.

RESUMEN

OBJECTIVE:To provide reference for clinical rational drug use. METHODS:Combined with bacterial drug resis-tance monitoring data in our hospital in 2014,the varieties,the amount of antibacterial drug,DDDs and other index were analyzed retrospectively for the same period. RESULTS:The detection rate of Gram-negative bacteria (79.27%) was higher than that of Gram-positive bacteria (20.73%);the most common Gram-negative bacilli and Gram-positive cocci were Escherichia coli (38.62%) and Staphylococcus aureus (5.22%). Pseudomonas aeruginosa and Stenotrophomonas maltophilia were the most com-mon non-fermentation bacteria;Main Gram positive bacteria were most sensitive to vancomycin,tigecycline and furadantin,etc. Main Gram-negative bacteria were most sensitive to imipenem,ertapenem,etc. Top 3 antibacterial drug in the list of DDDs were Levofloxacin injection,Cefazolin injection,Cefoperazone/sodium sulbactam for injection. CONCLUSIONS:Third generation of cephalosporins are used frequently in our hospital,which is a major cause of ESBLs producing and drug resistance,bacterial drug resistance monitoring and early warning data has played a positive role on guiding reasonable application of antibacterial drug in our hospital.